May 28, 2025 05:23 AM EDTUpdated 06:24 AM

InflaRx cans Gohibic development after skin disease trial stopped for futility

Elizabeth Cairns

Senior biopharma journalist

InflaRx will cease work on its intravenous complement inhibitor Gohibic for the skin condition pyoderma gangrenosum after an interim analysis indicated that a Phase 3 …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

InflaRx cans Gohibic development after skin disease trial stopped for futility

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

From weeks to days: how Aizon Intelligent Agents transform pharma validation

In­flaRx cans Go­hibic de­vel­op­ment af­ter skin dis­ease tri­al stopped for fu­til­i­ty

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

Up­dat­ed: Trump ad­min­is­tra­tion halts more than $750M in funds for Mod­er­na’s bird flu vac­cine

Pep­Gen ditch­es Duchenne pro­grams af­ter mid-stage fail, switch­es to pre­vi­ous­ly halt­ed mus­cle wast­ing ther­a­py

Oric locks down cash for Phase 3 prostate can­cer tri­al with ear­ly da­ta in hand

Ex­clu­sive: Move­ment dis­or­der biotech Vi­ma steps on­to scene with $60M

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

InflaRx cans Gohibic development after skin disease trial stopped for futility

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

Updated: Trump administration halts more than $750M in funds for Moderna’s bird flu vaccine

PepGen ditches Duchenne programs after mid-stage fail, switches to previously halted muscle wasting therapy

Oric locks down cash for Phase 3 prostate cancer trial with early data in hand

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

From weeks to days: how Aizon Intelligent Agents transform pharma validation